Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics Inc (NQ: ELTX )

4.900 +0.370 (+8.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 28,819
Open 4.640
Bid (Size) 4.600 (1)
Ask (Size) 5.250 (5)
Prev. Close 4.530
Today's Range 4.550 - 4.900
52wk Range 2.960 - 11.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. 
Via Benzinga
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
-17.37%
-17.37%
1 Month
-31.37%
-31.37%
3 Month
-47.03%
-47.03%
6 Month
+48.48%
+48.48%
1 Year
-47.37%
-47.37%

More News

Read More
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P
Via News Direct
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
Via News Direct
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
Via News Direct
Topics Death
Exposures Death
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
Via InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
Via News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Publication Of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
Via Benzinga
First Patient Dosed In Phase 2 Study Of Elicio Therapeutics' ELI-002 7P
Via Benzinga
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutics' AMPLIFY-201 Phase 1 Solid Tumor Study Of ELI-002
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.